NASDAQ:KLRS Kalaris Therapeutics Q3 2026 Earnings Results & Report $2.04 -0.26 (-11.13%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Kalaris Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.46 versus the -$0.52 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market Opens Kalaris Therapeutics EPS ResultsActual EPS-$0.46Consensus EPS -$0.52Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate5 of last 6 quartersKalaris Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Kalaris Therapeutics Q3 2026 Earnings FAQ Did Kalaris Therapeutics beat earnings estimates for Q3 2026? Kalaris Therapeutics (NASDAQ:KLRS) reported earnings of -$0.46 per share for Q3 2026, beating the consensus estimate of -$0.52. The report was announced on Tuesday, November 10, 2026. Kalaris Therapeutics Earnings HeadlinesKalaris Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 10 at 7:30 AM | globenewswire.comKalaris Therapeutics (NASDAQ:KLRS) Stock Rating Lowered by Wall Street ZenNovember 8 at 1:07 AM | americanbankingnews.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 10 at 1:00 AM | American Alternative (Ad)Kalaris Therapeutics (NASDAQ:KLRS) Stock Rating Raised to "Hold" at Wall Street ZenOctober 31, 2026 | americanbankingnews.comKalaris Therapeutics Inc (KLRS)October 3, 2026 | investing.comKalaris to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comSee More Kalaris Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kalaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kalaris Therapeutics and other key companies, straight to your email. Email Address About Kalaris TherapeuticsKalaris Therapeutics (NASDAQ:KLRS), Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina. Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities. The company’s activities primarily center on research, clinical development, and the potential commercialization of ophthalmic medicines. Publicly available information about Kalaris Therapeutics’ operating history, geographic commercial presence, and leadership is limited.View Kalaris Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
